News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Aton Pharma, Inc. Appoints Dr. Wayne Mulcahy to Vice President, Clinical Operations



2/16/2010 9:03:09 AM

LAWRENCEVILLE, N.J., Feb. 16 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, announced today that Wayne S. Mulcahy, Ph.D., has joined the company as Vice President, Clinical Operations. A wholly owned subsidiary of Princeton Pharma Holdings LLC, Aton is focused on the development and commercialization of unique products in ophthalmology and orphan diseases.

With more than 30 years of experience in clinical operations, Dr. Mulcahy has been responsible for the development and management of clinical programs across a range of therapeutic classes, including cardiovascular and CNS disorders, experience which is highly relevant to the clinical programs he will lead for Aton.

Prior to joining Aton, Dr. Mulcahy served as Vice President of Research and Development at Alita Pharmaceuticals, as Vice President of Clinical Operations at the Duramed Research subsidiary of Barr Pharmaceuticals and as Senior Director of Scientific and Regulatory Affairs at Teva Pharmaceuticals North America. He began his pharmaceutical career at Merck Research Laboratories where he was awarded a Doctoral Study Fellowship. Dr. Mulcahy earned his Ph.D. in pharmacology from Temple University School of Medicine, an M.S. from Drexel University and his B.A. from Arcadia University.

Aton Pharma, Inc.



Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES